search
Back to results

Role of Intravenous Lipid Emulsion in Improving Coma of Acute Antipsychotics Poisoning

Primary Purpose

Coma

Status
Unknown status
Phase
Not Applicable
Locations
Egypt
Study Type
Interventional
Intervention
Intravenous Lipid Emulsion (Intralipid 20%)
Sponsored by
Ain Shams University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Coma focused on measuring Coma /antipsychotics/ lipid emulsion/acute toxicity

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All adult comatose patients admitted to the ICU of Poison Control Center of Ain Shams University Hospitals with positive history of antisychotic drugs overdose during the period starting from the beginning of March 2020 to the end of Septemper 2021

Exclusion Criteria:

  • Based on the possibility of heterogeneity in hemodynamic parameters, laboratory variables, GCS and/or AVPU Scale, the following patients will be excluded:

    • Patients less than 18 years and more than 65 years.
    • Pregnant and lactating females.
    • Co-ingestion of other agents.
    • Presence of medical diseases (e.g. renal, hepatic, cardiovascular diseases) and chronic pancreatitis.
    • History of head trauma.
    • Presence of conditions where ILE is contraindicated.

Sites / Locations

  • Hend salama shalby El FarRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Other

Other

Arm Label

Group A (control)

Group B (case)

Arm Description

Group A (control): that will receive the traditional supportive treatment for acute antipsychotic drugs overdose

that will receive the traditional supportive treatment for acute antipsychotic drugs overdose plus administration of 1.5 ml/kg ILE (20%) as a bolus over 1-2 minutes, followed by a continuous rate infusion of 0.25 ml/kg/min for the next 30 to 60 minutes

Outcomes

Primary Outcome Measures

Complete recovery
Regaining consciousness with galasco coma scale 15/15 without presence of other clinical manifestations denoting antipsychotics toxicity.

Secondary Outcome Measures

Full Information

First Posted
February 10, 2021
Last Updated
March 17, 2021
Sponsor
Ain Shams University
search

1. Study Identification

Unique Protocol Identification Number
NCT04807634
Brief Title
Role of Intravenous Lipid Emulsion in Improving Coma of Acute Antipsychotics Poisoning
Official Title
Role of Intravenous Lipid Emulsion in Improving Coma of Acute Antipsychotics Poisoning: A Randomized Controlled Trial in PoisonControl Center of Ain Shams University Hospitals
Study Type
Interventional

2. Study Status

Record Verification Date
March 2021
Overall Recruitment Status
Unknown status
Study Start Date
March 10, 2021 (Actual)
Primary Completion Date
September 2021 (Anticipated)
Study Completion Date
September 2021 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Ain Shams University

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No

5. Study Description

Brief Summary
Intravenous Lipid Emulsion in Improving Coma Of Antipsychotic drugs Acute Poisoning: A Randomized Controlled Trial in Poison Control Center of Ain Shams University Hospitals
Detailed Description
Intravenous lipid emulsions (ILEs) have been recently used in treatment of acute toxicity caused by lipophilic drugs including local anesthetics, antidepressants, anti-arrhythmics, beta blockers and calcium channel antagonists with few case reports concerning their use in treatment of acute antipsychotics overdose (Muller et al., 2015). To the best of our knowledge, no randomized controlled trials (RCTs) have been performed to evaluate the antidotal effect of ILEs on the level of consciousness of acutely poisoned patients by antipsychotics and their routine metabolic profile tests. Acute poisoning by antipsychotics could result in various life-threatening toxic effects mainly on cardiovascular and central nervous systems (CNS). Tachycardia, hypotension, and QT prolongation in electrocardiogram are the most common cardiovascular findings while sedation, extrapyramidal symptoms, agitation, and coma are the most common CNS findings following acute antipsychotic exposures (Divac et al., 2014). As acute antipsychotic drugs overdose lack specific antidote, the primary goal in treatment is aggressive supportive therapy. In order to prevent CNS depression and respiratory failure, patients may need to be supported by mechanical ventilation. Hypotension is treated by intravenous fluids with use of direct-acting vasopressors (Orazel et al., 2019). Several mechanisms for the antidotal properties of ILEs have been proposed including their ability to capture lipophilic drugs and extract them from vital organs such as the heart and brain thus reducing their toxicity, preferential distribution of lipophilic drugs into a circulating lipid phase, thereby reducing tissue drug concentrations. In addition, ILEs have direct inotropic effect due to improved fatty acid oxidative metabolism resulting in restoration of myocardial contractility (Zyoud et al., 2016 & Kehayova et al., 2019). Sample size: • Based on the calculated sample size by statistics committee (Community Medicine, Environmental, and Occupational Medicine Department - Faculty of Medicine, Ain shams University), a total of at least 30 patients with history of acute intoxication by antipsychotic drugs will be enrolled and randomly assigned into case (n=15) and control (n=15) groups. Method of rondamization: • Randomization will be achieved via a computer-generated random -sequence table. On admission, the patient will receive the conventional management including history taking, clinical examination, investigations and treatment . Examination will be repeated every six hours through the period of hospital stay of the patient. All clinical data of the patient will be recorded in a special sheet that include the following data : Sociodemographic data: Age. Gender. Residence Intoxication data: Type of antipsychotic drug responsible for intoxication. Amount of antipsychotic drug (if available). Mode of poisoning, whether suicidal, accidental, criminal or therapeutic error. Route of intake of the poison. Time elapsed between the exposure and arrival to the PCC-ASU (delay time). Preconsultation management. Presence of comorbidities (as underlying medical or psychiatric diseases). The current medications used by the patient including all drugs used in treatment of diseases. Clinical data (on admission and during hospital stay): In both groups, detailed examination of the patients will be carried out on admission and routinely according to the severity of poisoning. Assessment of the level of consciousness of all patients under the study will be carried out on admission and every six hours by using Glasgow coma scale (GCS) and Alert, Voice, Pain, Unresponsive (AVPU) scale till the patient discharge or mortality. Investigations: Laboratory: all required laboratory investigations will be performed including arterial blood gas (ABG) analysis, and routine metabolic profile tests (e.g. glucose, sodium, potassium, urea and creatinine). Other required investigations: Electrocardigraphy (ECG) will be done on admission and 12 h later, then every 24 h till the patient discharge or mortality.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Coma
Keywords
Coma /antipsychotics/ lipid emulsion/acute toxicity

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Randomized controlled trial (RCT).
Masking
None (Open Label)
Allocation
Randomized
Enrollment
30 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Group A (control)
Arm Type
Other
Arm Description
Group A (control): that will receive the traditional supportive treatment for acute antipsychotic drugs overdose
Arm Title
Group B (case)
Arm Type
Other
Arm Description
that will receive the traditional supportive treatment for acute antipsychotic drugs overdose plus administration of 1.5 ml/kg ILE (20%) as a bolus over 1-2 minutes, followed by a continuous rate infusion of 0.25 ml/kg/min for the next 30 to 60 minutes
Intervention Type
Drug
Intervention Name(s)
Intravenous Lipid Emulsion (Intralipid 20%)
Other Intervention Name(s)
Intralipid 20%
Intervention Description
Lipid emulsion or fat emulsion refers to an emulsion of lipid for human intravenous use. It is often referred to by the brand name of the most commonly used version, Intralipid, which is an emulsion of soy bean oil, egg phospholipids and glycerin, and is available in 10%, 20% and 30% concentrations. The 30% concentration is not approved for direct intravenous infusion, but should be mixed with amino acids and dextrose as part of a total nutrient admixture.
Primary Outcome Measure Information:
Title
Complete recovery
Description
Regaining consciousness with galasco coma scale 15/15 without presence of other clinical manifestations denoting antipsychotics toxicity.
Time Frame
6 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All adult comatose patients admitted to the ICU of Poison Control Center of Ain Shams University Hospitals with positive history of antisychotic drugs overdose during the period starting from the beginning of March 2020 to the end of Septemper 2021 Exclusion Criteria: Based on the possibility of heterogeneity in hemodynamic parameters, laboratory variables, GCS and/or AVPU Scale, the following patients will be excluded: Patients less than 18 years and more than 65 years. Pregnant and lactating females. Co-ingestion of other agents. Presence of medical diseases (e.g. renal, hepatic, cardiovascular diseases) and chronic pancreatitis. History of head trauma. Presence of conditions where ILE is contraindicated.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Enas A El Taftazani, Professor
Phone
01223946023
Ext
02
Email
enas.taft@gmail.com
First Name & Middle Initial & Last Name or Official Title & Degree
Walaa G Abdel Hamid, Lecturer
Phone
01062261010
Ext
02
Email
Walaagomaa@outlook.com
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Manal A Abdel Salam, Professor
Organizational Affiliation
Ain Shams University
Official's Role
Study Chair
Facility Information:
Facility Name
Hend salama shalby El Far
City
Cairo
Country
Egypt
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Hend Salama, resident
Phone
01005403711
Email
hendsalam149@gmail.com
First Name & Middle Initial & Last Name & Degree
Walaa Gomaa, lecturer
Phone
01062261010
Email
Walaagomaa@outlook.com

12. IPD Sharing Statement

Citations:
PubMed Identifier
26945707
Citation
Berling I, Buckley NA, Isbister GK. The antipsychotic story: changes in prescriptions and overdose without better safety. Br J Clin Pharmacol. 2016 Jul;82(1):249-54. doi: 10.1111/bcp.12927. Epub 2016 Apr 15.
Results Reference
background
PubMed Identifier
24995318
Citation
Divac N, Prostran M, Jakovcevski I, Cerovac N. Second-generation antipsychotics and extrapyramidal adverse effects. Biomed Res Int. 2014;2014:656370. doi: 10.1155/2014/656370. Epub 2014 Jun 3.
Results Reference
background
PubMed Identifier
22668123
Citation
Levine M, Ruha AM. Overdose of atypical antipsychotics: clinical presentation, mechanisms of toxicity and management. CNS Drugs. 2012 Jul 1;26(7):601-11. doi: 10.2165/11631640-000000000-00000. Erratum In: CNS Drugs. 2012 Sep 1;26(9):812.
Results Reference
background
PubMed Identifier
26049929
Citation
Muller SH, Diaz JH, Kaye AD. Clinical applications of intravenous lipid emulsion therapy. J Anesth. 2015 Dec;29(6):920-6. doi: 10.1007/s00540-015-2036-6. Epub 2015 Jun 7.
Results Reference
background
PubMed Identifier
27098056
Citation
Zyoud SH, Waring WS, Al-Jabi SW, Sweileh WM, Rahhal B, Awang R. Intravenous Lipid Emulsion as an Antidote for the Treatment of Acute Poisoning: A Bibliometric Analysis of Human and Animal Studies. Basic Clin Pharmacol Toxicol. 2016 Nov;119(5):512-519. doi: 10.1111/bcpt.12609. Epub 2016 May 20.
Results Reference
background

Learn more about this trial

Role of Intravenous Lipid Emulsion in Improving Coma of Acute Antipsychotics Poisoning

We'll reach out to this number within 24 hrs